Earnings ·
aTyr Pharma reports Q3 net loss of $18.3M, ends quarter with $50.3M cash
ATYRaTYR PHARMA Inc
aTyr Pharma reported a third-quarter 2026 net loss of $18.3 million, or $7.43 per share, compared to a $25.7 million loss in the prior-year period. Research and development expenses decreased to $10.4 million from $22.1 million as the company shifted focus toward strategic partnerships for its lead candidate efzofitimod. The firm ended the quarter with $50.3 million in cash, cash equivalents, restricted cash, and investments, projecting a runway into late 2028 based on current operational plans. Additionally, the company reached FDA alignment on the protocol for a Phase 3 study of efzofitimod in pulmonary sarcoidosis and completed enrollment in its Phase 2 systemic sclerosis trial.